To examine whether our results in the Eμ-Myc mouse model could be applied to human cancer cells, we performed a whole genome CRISPR/Cas9 KO screen in the human Burkitt lymphoma cell line BL2 that has wildtype TP53 and is highly sensitive to MCL-1 inhibition [24]. This evidence concerns the gene MCL1 and Burkitt lymphoma.